(NASDAQ: DYN) Dyne Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 37.26%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 41%.
Dyne Therapeutics's earnings in 2025 is -$412,885,000.On average, 18 Wall Street analysts forecast DYN's earnings for 2025 to be -$526,276,253, with the lowest DYN earnings forecast at -$609,258,693, and the highest DYN earnings forecast at -$479,499,936. On average, 17 Wall Street analysts forecast DYN's earnings for 2026 to be -$506,857,253, with the lowest DYN earnings forecast at -$690,121,403, and the highest DYN earnings forecast at -$419,749,165.
In 2027, DYN is forecast to generate -$440,405,860 in earnings, with the lowest earnings forecast at -$758,436,451 and the highest earnings forecast at -$315,185,316.